Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.84 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.84 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.84 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | FABP3 | P05413 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | GMNN | O75496 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | BLM | P54132 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15477711 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477474 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477746 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL1292651 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477633 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL159631 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL9951509 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477814 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL2221345 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477665 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4239331-B1 | A METHOD OF PROCESSING A BIOLOGICAL SAMPLE | METABOLOMIC DIAGNOSTICS LTD (IE) | 2025-11-05 | — | — | EP | claimed |
| US-20250012811-A1 | METHODS OF PREDICTING PRE TERM BIRTH FROM PREECLAMPSIA USING METABOLIC AND PROTEIN BIOMARKERS | Metabolomic Diagnostics Limited (IE) | 2025-01-09 | — | — | US | claimed |
| EP-4239331-A1 | A METHOD OF PROCESSING A BIOLOGICAL SAMPLE | Metabolomic Diagnostics Limited (IE) | 2023-09-06 | — | — | EP | claimed |
| US-11698361-B1 | Method of processing a biological sample | Metabolomic Diagnostics Limited (IE) | 2023-07-11 | — | — | US | claimed |
| US-20220181030-A1 | DETECTION OF RISK OF PRE-ECLAMPSIA IN OBESE PREGNANT WOMEN | Metabolomic Diagnostics Limited (IE) | 2022-06-09 | — | — | US | claimed |
| EP-3918338-A1 | DETECTION OF RISK OF PRE-ECLAMPSIA IN OBESE PREGNANT WOMEN | Metabolomic Diagnostics Limited (IE) | 2021-12-08 | — | — | EP | claimed |
| CN-113748344-A | Detection of risk of pre-eclampsia in obese pregnant women | 代谢组学诊断有限公司 | 2021-12-03 | — | — | CN | claimed |
| US-20210033619-A1 | METHODS OF PREDICTING PRE TERM BIRTH FROM PREECLAMPSIA USING METABOLIC AND PROTEIN BIOMARKERS | Metabolomic Diagnostics Limited (IE) | 2021-02-04 | — | — | US | claimed |
| EP-3749952-A2 | A METHOD OF PROCESSING A BIOLOGICAL SAMPLE | Metabolomic Diagnostics Limited (IE) | 2020-12-16 | — | — | EP | claimed |
| WO-2020157021-A1 | DETECTION OF RISK OF PRE-ECLAMPSIA IN OBESE PREGNANT WOMEN | Metabolomic Diagnostics Limited (IE) | 2020-08-06 | — | — | WO | claimed |
| EP-3285814-B1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-06-24 | — | — | EP | claimed |
| WO-2019155057-A2 | A METHOD OF PROCESSING A BIOLOGICAL SAMPLE | Metabolomic Diagnostics Limited (IE) | 2019-08-15 | — | — | WO | claimed |
| US-20180140725-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-05-24 | — | — | US | claimed |
| EP-3285814-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | Memorial Sloan-Kettering Cancer Center (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2016172146-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-10-27 | — | — | WO | claimed |
| EP-4742268-A2 | A METHOD OF GENERATING A STATISTICAL MODEL TO DETECT, OR PREDICT THE RISK OF, AN OUTCOME | Metabolomic Diagnostics Limited (IE) | 2026-05-13 | — | — | EP | disclosed |
| CN-121577790-A | Application of metabolic marker in preparation of eye myasthenia gravis diagnostic reagent | 西安市第一医院 | 2026-02-27 | — | — | CN | disclosed |
| US-20070265216-A1 | ENHANCED MEDICAL TREATMENT IN DIABETIC CARDIOMYOPATHY | WASHINGTON UNIVERSITY IN ST. LOUIS | 2007-11-15 | — | — | US | disclosed |
| US-20070148779-A1 | Multidimensional mass spectrometry or serum and celluar lipids directly from biologic extracts | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2007-06-28 | — | — | US | disclosed |
| US-20040191916-A1 | Multidimensional mass spectrometry of serum and cellular lipids directly from biologic extracts | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265216-A1 | ENHANCED MEDICAL TREATMENT IN DIABETIC CARDIOMYOPATHY | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 1857/4885NR5A2 3463/4885NR5A1 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.